Podcasts about Immunotherapy

Activation or suppression of the immune system to treat disease

  • 971PODCASTS
  • 4,792EPISODES
  • 43mAVG DURATION
  • 1DAILY NEW EPISODE
  • May 28, 2025LATEST
Immunotherapy

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Immunotherapy

Show all podcasts related to immunotherapy

Latest podcast episodes about Immunotherapy

The Cancer Pod: A Resource for Cancer Patients, Survivors, Caregivers & Everyone In Between.
Does Timing Matter? Treatment Outcomes and Cancer Fatigue

The Cancer Pod: A Resource for Cancer Patients, Survivors, Caregivers & Everyone In Between.

Play Episode Listen Later May 28, 2025 36:48 Transcription Available


What if something as simple as a morning versus an afternoon infusion determined whether your immune treatment works? A recent study of over 1600 patients shows that time of day can profoundly affect whether you derive benefit (ie, “respond to treatment”)!  This episode also explores how time-restricted eating can affect your fatigue (called “chrono-nutrition”) during and after treatment. Join Drs. Tina Kaczor and Leah Sherman as they bring you the latest evidence and tell you how you can use your own circadian rhythm to your advantage.The study of over 1600 patients receiving immune therapy, response and time of dayThe study on Time Restricted Eating and Fatigue we talk aboutA questionnaire to track the severity of overall symptomsThe Brief Fatigue Inventory, a good way to track fatigueA study on timed eating for those with brain metastasis Support the showOur website: https://www.thecancerpod.com Become a member of The Cancer Pod Community! Gain access to live events, exclusive content, and so much more. Join us today and be part of the journey!Email us: thecancerpod@gmail.com Follow @TheCancerPod on: Instagram Bluesky Facebook LinkedIn YouTube THANK YOU for listening!

OffScrip with Matthew Zachary
Constellations and Cancer: A Storytelling Rebellion with Lisa Shufro

OffScrip with Matthew Zachary

Play Episode Listen Later May 27, 2025 40:11


EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Don't Ignore the Nudge
God's Kingdom, God's Way Part 1

Don't Ignore the Nudge

Play Episode Listen Later May 25, 2025 32:50


Have you ever wished that there would be a world renown doctor who not only was great at his profession, but also loved the Lord??  Well, today you'll meet Dr. Tony Jimenez, founder and Chief Medical Officer of Hope4Cancer, one of the best places in the world to get treatment.  Where does the Lord fit in?  IN AND THROUGHOUT our whole conversation.  Enjoy!Reach Out to Me:Website: www.dontignorethenudge.comPatreon: www.patreon.com/dontignorethenudgeIG: @dontignorethenudgepodcastPrivate FB group to WATCH interviews: www.dontignorethenudge.com/facebook__________________________________________________________________________________________Business/Personal Coaching with Cori:www.corifreeman.com(951) 923-2674

Oncotarget
Immune Side Effects of Liver Cancer Therapy Studied in Latin American Patients

Oncotarget

Play Episode Listen Later May 23, 2025 4:16


BUFFALO, NY - May 23, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma." The study, led by first authors Leonardo Gomes da Fonseca from Hospital das Clínicas, Universidade de São Paulo, Brazil, and Federico Piñero from Hospital Universitario Austral, Argentina, investigated how patients with advanced liver cancer in Latin America respond to a widely used immunotherapy combination. The researchers found that although a minority of patients developed immune-related side effects, these events did not significantly impact overall survival. Their findings highlight the importance of early recognition and careful management of such side effects in real-world clinical settings. Liver cancer is a leading cause of cancer deaths worldwide, with limited treatment options for patients diagnosed at an advanced stage. Immunotherapy, particularly the combination of atezolizumab and bevacizumab, has become a standard approach. However, these treatments can sometimes trigger the body's immune system to attack healthy organs, leading to what are called immune-related adverse events, or irAEs. Until now, little data existed on how frequently these events occur in Latin American patients and whether they impact treatment outcomes. The researchers followed 99 patients from Argentina, Brazil, Chile, and Colombia, most of whom had cirrhosis or underlying liver disease. They received atezolizumab and bevacizumab for a median duration of six months. The researchers reported that only 18% of the patients experienced immune-related side effects, most commonly affecting the liver (hepatitis) and thyroid (thyroiditis). Most of these cases were mild or moderate, and half of them resolved completely within a month. Only eight patients needed treatment with steroids to control the immune response. Importantly, the occurrence of immune-related side effects did not affect how long patients survived after starting treatment. The median survival was the same—18.5 months—for both those who experienced irAEs and those who did not. This result suggests that while irAEs require careful management, they may not reduce the overall benefits of immunotherapy. Another significant finding was that patients with higher levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, were more likely to experience these side effects. This information could help clinicians identify patients who need closer control during treatment. “Notably, baseline alpha-fetoprotein (AFP) values ≥400 ng/ml were significantly associated with the development of irAEs.” The study also points to key differences between clinical trial results and real-world experiences. While clinical trials report higher rates of side effects, this real-world data showed a lower incidence, possibly due to less intensive monitoring or differences in how side effects are documented in everyday practice. In summary, this study highlights that patients require ongoing vigilance and individualized care when treating liver cancer with immunotherapy. It provides valuable information to healthcare providers in Latin America and other regions with similar patient populations, aiming to improve outcomes while minimizing risks. DOI - https://doi.org/10.18632/oncotarget.28721 Correspondence to - Federico Piñero - fpinerof@cas.austral.edu.ar To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

Oncotarget
Combining Radiation and Immunotherapy Shows Promise for Bladder Cancer

Oncotarget

Play Episode Listen Later May 21, 2025 3:45


BUFFALO, NY - May 21, 2025 – A new #review was #published in Volume 16 of Oncotarget on May 19, 2025, titled “Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy." Researchers from the University of California, Irvine, led by Nazmul Hasan, reviewed recent clinical and scientific advances in combining radiation therapy with immunotherapy for bladder cancer. The article summarizes growing evidence that this combined approach may strengthen the immune response and improve long-term disease control. This strategy is especially important for patients who are not candidates for surgery or who respond poorly to conventional treatments. Bladder cancer is a serious and frequent condition, particularly affecting older men. Traditional treatments—surgery, chemotherapy, and radiation—can be effective, but they often fail to prevent cancer reappearance in advanced cases. The review explores how combining radiation and immunotherapy could improve outcomes by helping the immune system detect and destroy cancer cells more effectively. Radiation therapy destroys cancer cells and triggers the release of tumor signals that attract immune cells. Immunotherapy, including drugs like pembrolizumab and nivolumab, helps the immune system work better by blocking proteins that allow cancer to evade detection. Used together, these treatments may produce a stronger, more widespread anti-tumor effect, even at distant sites not directly targeted by radiation. The review discusses several clinical trials that support this approach. One phase II study reported that combining radiation with the immunotherapy drug durvalumab led to promising survival rates and manageable side effects. Another trial in Australia tested pembrolizumab with radiation and chemotherapy, resulting in high tumor control and extended patient survival. However, the review also points out that other trials showed serious side effects when high doses or multiple immunotherapy drugs were used at once. "Joshi et al. performed a phase II study to determine the safety and efficacy of combining radiation therapy with durvalumab, a PD-L1 inhibitor, in patients who were ineligible for surgery or cisplatin-based chemotherapy." While the combination approach is promising, the authors emphasize that more research is needed to refine this treatment strategy. One major challenge is determining which patients are most likely to benefit. Future studies should focus on identifying reliable biomarkers, such as tumor mutation burden or immune activity, to guide personalized treatment plans. This review highlights the potential of combining radiation and immunotherapy to improve outcomes for bladder cancer patients. With continued research and careful treatment design, this approach could offer new treatment options for those facing aggressive or hard-to-treat forms of the disease. DOI - https://doi.org/10.18632/oncotarget.28723 Correspondence to - Nazmul Hasan - nhasan1@hs.uci.edu Video short - https://www.youtube.com/watch?v=AxrZhIUXrOQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28723 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, bladder cancer, immunotherapy, radiation, microenvironment, abscopal To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

OffScrip with Matthew Zachary
Dancing Through the Wreckage: Sally Wolf

OffScrip with Matthew Zachary

Play Episode Listen Later May 20, 2025 39:59


What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

People Behind the Science Podcast - Stories from Scientists about Science, Life, Research, and Science Careers
813: Investigating the Impacts of the Gut Microbiome on Immunotherapy Cancer Treatments - Dr. Jennifer Wargo

People Behind the Science Podcast - Stories from Scientists about Science, Life, Research, and Science Careers

Play Episode Listen Later May 19, 2025 35:18


Dr. Jennifer Wargo is an Associate Professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center and a Stand Up To Cancer researcher. Jennifer is a physician scientist, and this means she splits her time between providing care to patients and doing research to find better ways of treating disease. Specifically, Jennifer performs surgeries and treats patients one day each week. She spends the rest of her week studying how to better treat patients with cancer and how cancer may ultimately be prevented. When she's not doing research or treating patients, Jennifer enjoys spending quality time with her family. Some of their favorite activities include going for walks, biking, hiking, and visiting the beach. Jennifer also likes to explore her creative side through art and photography, as well as to be active through running, biking, yoga, and surfing. She received her A.S. degree in nursing and B.S. degree in biology from Gwynedd-Mercy College. Afterwards, Jennifer attended the Medical College of Pennsylvania where she earned her M.D. Jennifer completed her Clinical Internship and Residency in General Surgery at Massachusetts General Hospital. Next, Jennifer was a Research Fellow in Surgical Oncology at the University of California, Los Angeles. She then accepted a Clinical Residency in General Surgery at Massachusetts General Hospital. From 2006-2008, Jennifer was a Clinical Fellow in Surgical Oncology at the National Cancer Institute of the National Institutes of Health. She then served on the faculty at Massachusetts General Hospital and Harvard University. In 2012, Jennifer received her MMSc. degree in Medical Science from Harvard University. Jennifer joined the faculty at The University of Texas MD Anderson Cancer Center in 2013. She is Board Certified by the American Board of Surgery, and she has received numerous awards and honors throughout her career. These have included the R. Lee Clark Prize and Best Boss Award from the MD Anderson Cancer Center, the Rising STARS and The Regents' Health Research Scholars Awards from the University of Texas System, the Outstanding Young Investigator and Outstanding Investigator Awards from the Society for Melanoma Research, as well as a Stand Up To Cancer Innovative Research Grant for her microbiome work. She has also received other awards for excellence in teaching, research, and patient care. In our interview, Jennifer shares more about her life and science.

Research To Practice | Oncology Videos
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 18, 2025 50:15


Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics: Introduction (0:00) Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04) First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59) CME information and select publications

Lung Cancer Update
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit

Lung Cancer Update

Play Episode Listen Later May 18, 2025 50:15


Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  CME information and select publications here.

The Immunobuddies
Episode 142: Immunotherapy Reimagined Final Part - Taking a BITE out of the cancer cell

The Immunobuddies

Play Episode Listen Later May 16, 2025 32:13


Biotech 2050 Podcast
Stacy Lindborg, Imunon President & CEO, on Bold Biotech, IL-12 Immunotherapy & Phase 3 Trials

Biotech 2050 Podcast

Play Episode Listen Later May 14, 2025 17:56


Synopsis: What does bold biotech leadership look like in 2025? In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes. Stacy shares insights from her 30-year career—from her statistical roots at Eli Lilly to her mission-driven leadership at Imunon. She highlights the groundbreaking results from Imunon's IL-12 plasmid platform, which is showing a remarkable 13-month overall survival advantage in ovarian cancer patients and is now entering Phase 3 trials. They also discuss the evolving biotech landscape, how adaptive trial designs and AI are unlocking clinical potential, and why cultivating a bold, transparent company culture is key to advancing transformational science. Biography: Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon's Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company's Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners. Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&D strategy. Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.

Conversing
Treating Cancer, with Selwyn Vickers

Conversing

Play Episode Listen Later May 13, 2025 52:57


Cancer is among the most common and feared diseases in the modern world. Dr. Selwyn Vickers—president and CEO of Memorial Sloan Kettering Cancer Center—joins host Mark Labberton to discuss how precision oncology, data, and faith are transforming cancer treatment. A distinguished cancer surgeon and pancreatic cancer researcher, Vickers explains how groundbreaking advances in genomics, immunotherapy, and AI are transforming once-lethal diagnoses into survivable and even chronic conditions. Together, they explore not only the cutting-edge science of cancer care but also the spiritual, emotional, and social dimensions that affect every patient and caregiver. Resonating with themes of suffering, hope, and resurrection, this conversation offers clarity, compassion, and courage for all who are affected by cancer—from those newly diagnosed, to medical professionals, to grieving families and curious listeners. Episode Highlights “We're getting to a point where we will, in the next five to seven years, have a much better chance to cure people—and to make pancreatic cancer a chronic illness.” “We are in what's somewhat coined the golden age of cancer research.” “Cancer is a disease that creates an existential threat in ways no other illness does.” “If a tumour forms, it means your body's immune system has made a social contract with the cancer.” “We changed the diagnosis in 10–12 percent of the patients who come to us—sometimes from cancer to no cancer.” “Cancer care is a team sport. And our patients often inspire us more than we help them.” Helpful Links & Resources Memorial Sloan Kettering Cancer Center BioNTech – creators of mRNA vaccines for COVID and cancer CAR T-Cell Therapy Overview (Cancer.gov) Tim Keller on cancer and hope Emma Thompson's Wit (HBO) BRCA1 and BRCA2 Genes and Cancer Risk MSK-IMPACT: Next-Gen Tumor Profiling About Selwyn Vickers Selwyn M. Vickers, MD, FACS, is the president and CEO of Memorial Sloan Kettering Cancer Center (MSK) and the incumbent of the Douglas A. Warner III Chair. He assumed the role on September 19, 2022. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as president of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Vickers is the immediate past president of the American Surgical Association. He also continues to see patients. In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and Chair of the Department of Surgery at the University of Minnesota Medical School. Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two postgraduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children. Show Notes The ongoing threat and fear of cancer How Selwyn Vickers got into medicine Pancreatic cancer: Vickers's expertise “We are in what's somewhat coined the golden age of cancer research.” Sequencing the human genome “Is there a drug that might target the mutation that ended up creating your cancer?” Cancer as both a medical and existential diagnosis The revolution of precision oncology through human genome sequencing ”It takes a billion cells to have a one centimetre tumor.” Immunotherapy: checkpoint inhibition, CAR T-cell therapy, and vaccines Cellular therapy:   ”Taking a set of their normal cells and re-engineering them to actually go back and target and attack their tumors. … We've seen patients who had initially a 30 percent chance of survival converted to an 80 percent chance of survival.” “We know in many tumours there's something called minimal residual disease.” “Immunizing yourself against cancer is a significant future opportunity.” Managing the power of data with AI and computational oncology Cancer-care data explosion: the role of computational oncologists Cancer vaccines: breakthrough mRNA treatment for pancreatic cancer ”Didn't ultimately win. We had to suffer through her losing her life, but was so appreciative that she got much more than the six months she was promised.” Tumour misdiagnoses and the importance of specialized expertise Pancreatic cancer challenges: immune cloaking and late-stage detection In the past, one in four would die from the operation for removing pancreatic cancer Long-term survival Future of cancer detection: AI-based medical record analysis and blood biopsies More accurate blood tests to confirm conditions Using AI to select those who are high-risk for cancer Pastor Tim Keller died of pancreatic cancer. In the past, “your doctor … helped you learn how to die.” ”[God's] given man the privilege to discover those things that have been hidden. And over time we've gradually uncovered huge opportunities to impact people's lives.” The state of breast cancer research and treatment “If you get the diagnosis of breast cancer, you have a 90 percent chance to survive and beat it over a five-year period of time.” ”In general, we're in a great state of understanding how to treat breast cancer, how to detect it early, and then have selective and targeted mechanisms to prevent it from coming back.” Prostate cancer research and treatment Theranostics: using a specific antibody to target cancer cells specifically Pediatric cancer:  ”We actually treat more children for cancer than any hospital in America now, but in general, the survival for pediatric cancers is greater than 80 percent.” Emotional, psychological, and spiritual toll of cancer: importance of psycho-oncology How Sloan Kettering developed psycho-oncology to help cancer patients with mental and spiritual health Personal story: how a cafeteria worker empowers patients through food choices “We give back to them the right to choose what they get to have on their tray.” Cancer treatment is a team sport. Wit (film, Broadway play)—actress Emma Thompson plays a cancer patient studying the work of John Donne on death Socioeconomic and racial disparities in cancer care outcomes The healing role of community, support teams, and compassionate listening The importance of listening to cancer patients who are preparing to die The spiritual courage of patients and the transformative power of faith “Our patients often help us. We see the grace with which they often handle that journey.” The inspiration behind becoming a doctor: family legacy and human impact Terminal care: the sacred responsibility of walking with patients to the end Cancer research and treatment as a Christian vocation and expression of humanity Production Credits

Progress, Potential, and Possibilities
Dr. Samir Khleif, MD - CEO, Georgiamune Inc. - Reprogramming Immune Responses

Progress, Potential, and Possibilities

Play Episode Listen Later May 13, 2025 51:11


Send us a textDr. Samir Khleif, MD is CEO of Georgiamune ( https://www.georgiamune.com/team ), a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases.  Dr. Khleif is a pioneer in the field of immunotherapy. He is a medical oncologist, immunologist, innovator, and entrepreneur, as well as a transformational executive in health care and biomedical research.Prior to becoming CEO of Georgiamune, Dr. Khleif served in different academic and leadership positions. He was a National Cancer Institute (NCI)/National Institutes of Health (NIH) scientist and Chief of the NCI Cancer Vaccine Section, where he led the development of pioneering immune-oncology and cancer vaccines into clinical trials. As a national and international academic leader, and detailed by the US government, he served as the founding director and CEO of the King Hussein Cancer Center ( https://www.khcc.jo/en ) in Amman, Jordan, where he led the development of the largest cancer center in the MENA region. He also served as the director of the Georgia Cancer Center, the state cancer center, at Augusta University. He is currently a biomedical scholar and holds a professorship at Georgetown University Medical School.Dr. Khleif also served as a Special Assistant to the Commissioner of the FDA, leading the FDA's Critical Path Initiative for Oncology. He is a member of the board of directors of Ayala Pharmaceuticals and Emerald Biopharmaceutics, and served as a member of the scientific advisory board of more than 20 biotechnology and pharmaceutical companies.Dr. Khleif is an international KOL in immunology and immunotherapy. He has served on many national committees, including the Scientific Advisory Board of the Biden Cancer Initiative, as chair of the Immunotherapy Committee for NRG, and as a member of the NCI Cooperative Group. He currently serves as an advisor for the Parker Institute for Cancer Immunotherapy. Dr. Khleif is an editor of three books, the author of hundreds of peer-reviewed scientific research articles, and a prolific inventor with more than 150 patents issued or pending in the field of immunology and immunotherapy.Dr. Khleif received his medical degree at the University of Jordan, Amman Jordan. He completed his residency in Internal Medicine at the Medical College of Ohio and his fellowship in Medical Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland.#SamirKhleif #Georgiamune #Immunotherapy #KingHusseinCancerCenter #CriticalPathInitiative #FDA #Tregs #RegulatoryTCells #Cancer #Oncology #CheckpointInhibitors #ImmuneEscapeMechanisms #DualFunctioningAntibody #Autoimmune #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Oncologie Up-to-date
Adoptieve celtherapie en meer ontwikkelingen voor gevorderd en irresectabel melanoom

Oncologie Up-to-date

Play Episode Listen Later May 13, 2025 30:42


In de podcastserie proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze aflevering spreekt zij met dr. Maartje Rohaan over haar proefschrift, getiteld: “Immunotherapy for metastatic melanoma and beyond”. Maartje vertelt onder andere over de uitkomsten en impact van de TIL-studie, die zij coördineerde en analyseerde onder begeleiding van prof. dr. John Haanen, en die een waardevolle toevoeging is voor de behandeling van patiënten met een melanoom. Maartje heeft op 6 mei haar proefschrift succesvol verdedigd aan de Universiteit van Leiden bij prof. dr. John Haanen en dr. Sofie Wilgenhof.Referenties Inspiratietip: Het zoutpad – Raynor Winn TIL-studie MART-1 TCR-studie Neoadjuvante behandeling irresectable melanoom (REDUCTOR-studie)

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Jennifer Wargo, MD, MMSc - Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 12, 2025 82:03


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Jennifer Wargo, MD, MMSc - Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 12, 2025 82:03


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Jennifer Wargo, MD, MMSc - Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 12, 2025 82:03


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Jennifer Wargo, MD, MMSc - Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later May 12, 2025 82:03


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFB865. CME/MOC/AAPA/IPCE credit will be available until April 27, 2026.Unleashing Immunotherapy Against Resectable Melanoma: The Surgeon-Oncologist Alliance for Delivering Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Talking Features
Talking Health - The Grown Up Peanut Immunotherapy Trial

Talking Features

Play Episode Listen Later May 12, 2025 3:01


In this week's Talking Health, Jessica discusses the research conducted by King's College London and Guy's and St Thomas' NHS Foundation Trust called The Grown Up Peanut Immunotherapy trial.

Nurse Converse, presented by Nurse.org
Inside Oncology Nursing: Stories, Challenges, and Triumphs from the Frontlines of Cancer Care (With Rebeca Leon, MSN, RN)

Nurse Converse, presented by Nurse.org

Play Episode Listen Later May 8, 2025 36:45


Join Rebeca Leon on this episode of the Nurse Converse podcast as she pulls back the curtain on the world of oncology nursing. She shares her personal journey into this life-changing specialty, reflecting on the emotional highs, the profound patient connections, and the powerful community of oncology nurses. Get inspired by highlights from the 50th Oncology Nursing Society Congress and discover why this field is more critical than ever. If you've ever wondered what it's like to make a difference in the lives of cancer patients, this episode is for you. >>Inside Oncology Nursing: Stories, Challenges & Triumphs from the Frontlines of Cancer CareJump Ahead to Listen: [01:08] Oncology Nursing Society's 50th anniversary.[05:10] Oncology nursing specialties and settings.[10:57] Oncology nurses' resilience and care.[13:57] Attending oncology nursing conferences.[17:51] Customizing conference experiences for nurses.[23:45] Immunotherapy in oncology nursing.[26:00] Advancements in oncology nursing.[30:07] Oncology nursing opportunities for students.[34:37] Oncology nursing community connection.Connect with Rebeca on Social Media:Instagram: @EnfermeraMami.RNFor more information, full transcript and videos visit Nurse.org/podcastJoin our newsletter at nurse.org/joinInstagram: @nurse_orgTikTok: @nurse.orgFacebook: @nurse.orgYouTube: Nurse.org

Empowered Patient Podcast
Using Pulse Electric Field and Direct Tumor Injections to Target Advanced Cancers with Dr. Jason Williams The Williams Cancer Institute TRANSCRIPT

Empowered Patient Podcast

Play Episode Listen Later May 6, 2025


Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here

Empowered Patient Podcast
Using Pulse Electric Field and Direct Tumor Injections to Target Advanced Cancers with Dr. Jason Williams The Williams Cancer Institute

Empowered Patient Podcast

Play Episode Listen Later May 6, 2025 17:41


Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here

All Talk Oncology Podcast
⁠Beyond Chemo: How Direct Immunotherapy Is Changing Cancer Outcomes with Dr. Jason Williams

All Talk Oncology Podcast

Play Episode Listen Later May 5, 2025 35:13


What if cancer treatment could be made more effective by going straight to the source? In this episode of All Talk Oncology, Kenny Perkins sits down with Dr. Jason Williams, a pioneering interventional radiologist who is reshaping the future of cancer care through tumor-directed immunotherapy.   Dr. Williams shares how his childhood experience with his grandmother's breast cancer shaped his path toward developing innovative treatments. Instead of administering immunotherapy through traditional systemic methods, he and his team inject directly into tumors, enhancing immune response and potentially reducing side effects.   Key points discussed:   The origin and evolution of immunotherapy: from 2011 to now Why Dr. Williams transitioned from oncology to interventional radiology Direct tumor injection vs. systemic immunotherapy—why it matters Risks and overlooked dangers of traditional biopsy procedures How immune-stimulating drugs like Tocilizumab reduce side effects Addressing insurance limitations and off-label treatments The surprising link between Tylenol and immunotherapy effectiveness Clinical trials, success rates, and future directions in cancer treatment Why patients must take charge of their own care Immortalize your voice by being an ALL TALK ONCOLOGY GUEST! Just fill-out this FORM.   SOCIAL MEDIA LINKS: All Talk Oncology: Instagram & Facebook JOIN OUR FREE COMMUNITY: Facebook Community WEBSITE: https://www.alltalkoncology.com

BackTable Podcast
Ep. 538 Immunotherapy and TACE in HCC Treatment with Dr. Julius Chapiro and Dr. Richard Finn

BackTable Podcast

Play Episode Listen Later Apr 29, 2025 67:37


There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.---This podcast is supported by an educational grant from Guerbet.---SYNPOSISThe doctors highlight the importance of high quality clinical data and the pivotal studies shaping current best practices. They explore the role of the different players on the multidisciplinary team and compare the oncologic and radiologic perspectives. Additionally, they discuss the synergy between TACE and immunotherapy, the criteria for selecting appropriate treatments, and the ongoing need for research and collaboration.---TIMESTAMPS00:00 - Introduction 03:35 - HCC from an Oncologic Perspective 05:33 - Radiological Perspective on Liver Cancer06:50 - Referral Patterns and Organizing a Multidisciplinary Approach18:01 - Explaining TACE and Variations in the Procedure27:27 - Choosing the Right Procedure for HCC36:13 - Making a Decision on Medical Treatment Candidacy 42:23 - Importance of Data Driven HCC Treatment, Practical Insights, and Studies to Know55:30 - Planning an Approach for a TACE Procedure01:02:26 - Final Thoughts and Future Prospects in Liver Cancer Treatment---RESOURCESBarcelona Staging System:https://www.ncbi.nlm.nih.gov/books/NBK569796/table/Ch3-t0001/TRACE Trial:https://pubs.rsna.org/doi/full/10.1148/radiol.211806PREMIERE Trial:https://www.gastrojournal.org/article/S0016-5085(16)34971-X/fulltextEMERALD-1 Trial:https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.LBA432LEAP O12 Study:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

Keeping Current
Decoding PD-L1 Scoring: Guiding Immunotherapy for Gastroesophageal Cancers

Keeping Current

Play Episode Listen Later Apr 29, 2025 38:21


Did you know that tumor area positivity (TAP) scoring can be completed up to 6 times faster than combined positive score (CPS)?   Credit available for this activity expires: 4/23/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002476?ecd=bdc_podcast_libsyn_mscpedu

TODAY
TODAY April 28, 8AM: Breakthrough Treatment for Cancer | Christie Brinkley on ‘Uptown Girl' | Jim Cramer talks 20 Years of ‘Mad Money'

TODAY

Play Episode Listen Later Apr 28, 2025 32:37


An inside scoop into a groundbreaking study on the ways immunotherapy can avert the need for surgery or chemotherapy for certain cancer patients. Also, Christie Brinkley stops by to discuss her new memoir, ‘Uptown Girl.' She dives deep into her time in the spotlight and encourages readers to value the love in their lives. Plus, Jim Cramer talks about his twenty years on ‘Mad Money,' what listeners should expect from the economy, and how to react to those changes. And April Bestsellers is here to showcase all the best deals on everything from beauty to home goods. 

Everyone Dies (Every1Dies)
Understanding Cancer Treatment Options: Immunotherapy

Everyone Dies (Every1Dies)

Play Episode Listen Later Apr 26, 2025 30:06


Cancer cells often have ways to hide from immune cells. Immunotherapy is a type of cancer treatment that helps our body's own defenses - "Natural Born Killers" - to more effectively fight the cancer. Learn how: https://bit.ly/3S5rAfAIn this Episode:01:37 - Relishing New York's Finer Moments04:47 - New York Cheesecake Recipe08:08 - Anna Quindlen - Gratitude for the Moments11:17 - Immunotherapy, How it Works and TypesCancer VaccinesCheckpoint InhibitorsT Cell TransferMonoclonal AntibodiesImmune System Modulators 21:58 - Discussion - Is this Pretty New?25:26 - Worn Hands28:31 - Outro#immunity #everydayisagift #cancervaccine #immunotherapy #tcelltherapy #checkpointinhibitors #monoclonalantibodies #immunesystemmodulators #newyorkcheesecake #cancertreatment #cancerchoices #cancertherapy Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 24, 2025 64:16


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 24, 2025 64:16


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

The EMJ Podcast: Insights For Healthcare Professionals
Hema Now: Episode 15: Understanding B cell Metabolism in Lymphoma

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Apr 24, 2025 40:18


In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies.  Timestamps:      00:00 – Introduction  01:46 – Riches' journey into haematology  03:42 – What is T cell exhaustion?  07:06 – The key role of metabolism in lymphoma  09:33 - Richter's syndrome  13:17 – Breakthroughs in immunotherapy  20:27 – The challenges of translational research  25:39 – B cells in autoimmune diseases  28:16 – The potential of breath biopsy  32:58 – Riches' three wishes for healthcare 

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 24, 2025 64:16


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 24, 2025 64:16


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 24, 2025 64:16


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 24, 2025 64:16


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

FrequENTcy — AAO–HNS/F Otolaryngology Podcasts
Navigating Immunotherapy Options for Allergic Rhinitis: SCIT vs. SLIT

FrequENTcy — AAO–HNS/F Otolaryngology Podcasts

Play Episode Listen Later Apr 22, 2025 25:28


In this special edition of Voices of Otolaryngology, join Cecelia Damask, DO, and Matthew W. Ryan, MD, as they explore the critical differences between subcutaneous and sublingual immunotherapy for allergic rhinitis treatment. This in-depth discussion covers efficacy comparisons, safety profiles, cost considerations, and practical factors affecting patient adherence. Learn how these immunotherapy approaches can modify disease progression beyond symptom management and discover strategies for individualizing treatment plans for those suffering from allergic rhinitis.  Resources:  Clinical Practice Guideline: Immunotherapy for Inhalant Allergy https://www.entnet.org/quality-practice/quality-products/clinical-practice-guidelines/cpg-immunotherapy-for-inhalant-allergy/ ENThealth.org Treatment Options for Allergen Immunotherapy https://www.enthealth.org/be_ent_smart/treatment-options-for-allergen-immunotherapy-scit-vs-slit/ ENThealth.org FAQs about Allergen Immunotherapy https://www.enthealth.org/be_ent_smart/frequently-asked-questions-faqs-about-allergen-immunotherapy/

The Veterinary Roundtable
My Pets Wellness Shuts Down Overnight... What Went Wrong?

The Veterinary Roundtable

Play Episode Listen Later Apr 18, 2025 44:37


Send us an inquiry through a text message here!Welcome to another episode of The Veterinary Roundtable! In this episode, the ladies discuss the challenges of treating patients at a higher elevation, a handful of My Pets Wellness clinics closing overnight, keeping antimicrobial resistance in mind when treating patients, and more!Do you have a question, story, or inquiry for The Veterinary Roundtable? Send us a text from the link above, ask us on any social media platform, or email theveterinaryroundtable@gmail.com!Episodes of The Veterinary Roundtable are on all podcast services along with video form on YouTube!Instagram: https://tinyurl.com/2h27xnfuTikTok: https://tinyurl.com/m8f62ameYouTube: https://tinyurl.com/48njfywdTIMESTAMPSIntro 00:00Pits And Peaks 04:34Tails From The Trenches 11:32My Pets Wellness Closes All Vet Clinics Overnight 16:50New Immunotherapy Treatment May Delay Metastasis In Dogs With Osteosarcoma 21:18Case Collections 23:36Listener Loves Intranasal Bordetella 31:10Treating Patients At A Higher Elevation 34:00Keep Antimicrobial Resistance In Mind When Treating Patients 37:44Outro 44:28

FAACT's Roundtable
Ep. 229: International Oral Immunotherapy Guidelines

FAACT's Roundtable

Play Episode Listen Later Apr 16, 2025 18:00


Not long ago, 36 allergy experts worldwide came together to develop a consensus on preparing their patients for Oral Immunotherapy, also known as OIT. We're sitting down with FAACT's Medical Advisory Board Member, Dr. Katherine Anagnostou, one of the 36 allergy experts collaborating in the Preparing Patients for Oral Immunotherapy (PPOINT) consensus. Resources to keep you in the know:Preparing Patients for Oral Immunotherapy (PPOINT): international Delphi consensus for procedural preparation and consent - Journal of Allergy and Clinical ImmunologyYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Thanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Extreme Health Radio
Kate’s Journey Towards Shrinking Fibroids With Cannabis, Low Dose Immunotherapy, The Dangers Of Tattoo Inks, Self Care Ideas & Much More

Extreme Health Radio

Play Episode Listen Later Apr 11, 2025 60:58


Today was a fun show that we just got done recording. If you’re interested make sure to visit Kate’s new website. She’s blogging on there quite often.

The EMJ Podcast: Insights For Healthcare Professionals
Hema Now: Episode 14: Personalised Approaches in Myeloma Treatment

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Apr 9, 2025 36:17


This week, Jonathan is joined by Shaji Kumar, an expert in hematology and oncology, particularly multiple myeloma, who has made significant contributions to both clinical and translational science. Timestamps:  (00:00) – Introduction   (02:23) – Drug combinations and myeloma biology  (08:34) – Treating newly diagnosed multiple myeloma  (17:24) – Quadruplet regimens   (23:09) – Clinical trials for plasma cell malignancies  (28:04) – The bone marrow microenvironment in multiple myeloma  (30:29) – “Blind men and an elephant”  (33:58) – Kumar's three wishes for healthcare   

Conversations
The wisdom of an ancient Pencil Pine

Conversations

Play Episode Listen Later Apr 8, 2025 52:12


Nature writer Andrew Darby on what he learned from his rambles through the wilds of Tasmania, communing with the world's oldest surviving trees. In particular, his ‘buttock clenching' ascent up a 60-metre-tall eucalyptus known as The Vibe Tower.Nature writer, Andrew Darby spent more than 20 years as a Fairfax correspondent based in Tasmania.His stories involved the natural beauty of the bush, including visits to wild places and to the people who protect them, but it was deadline-driven and he couldn't spend the time he wanted to.In 2017 Andrew was diagnosed with stage four lung cancer.He underwent immunotherapy and was given a maximum 18-months to live. It has been eight years since he entered his “second life”.Andrew was determined to fully inhabit his beloved Tasmanian bush, so he went by himself to commune with ancient trees.These are some of the world's oldest surviving trees, like King's Lomatia; some of the biggest trees, like a 60-metre-tall eucalyptus known as The Vibe Tower; and Andrew's favourite, the dignified Pencil Pine.The Ancients: Discovering the world's oldest surviving trees in wild Tasmania is published by Allen & Unwin.This episode of Conversations touches on wild Tasmania, ancient trees, Pencil Pine, King's Lomatia, King Billy Pine, Giant Eucalyptus, Peter Dombrovskis photography, Walls of Jerusalem National Park, Pool of Siloam, epic hike, solo hike, stage four lung cancer, immunotherapy, second life and loving nature, hikes of Australia.

Boob to Food - The Podcast
120 – Allergy FAQs and Oral Immunotherapy with Dr Chaitanya Bodapati

Boob to Food - The Podcast

Play Episode Listen Later Apr 8, 2025 28:54


Dr Chai is back for a third time on the podcast to help us navigate some of the most frequently asked questions about food allergies—this time diving into the grey areas that many families feel confused about, like breastfeeding and allergens, eczema and food introduction, and the difference between allergies and intolerances. We also explore a hot topic in the allergy world right now: oral immunotherapy (or desensitisation).Dr Chaitanya Bodapati is a dual-trained Paediatric Allergy/Immunology Specialist and General Paediatrician. With a holistic and family-centred approach, Dr Chai blends her clinical expertise with her personal experience as a mum of children with food allergies. Her relatable and evidence-based support helps families feel confident and informed at every stage of their allergy journey.In this episode we discuss:Breastfeeding with food allergies The difference between an allergy and an intoleranceHow to manage eczema when introducing solids and allergensIf food-based skincare products (like almond oil or coconut oil) increase the risk of allergiesWhether what you eat in pregnancy or breastfeeding affects your baby's allergy riskWhy formula-fed babies may already be exposed to some allergensWhat oral immunotherapy is and who it might be suited toWhy food allergy desensitisation is becoming more common in Australia… and so much more!You can connect with Dr Chai via Instagram at @childrensallergyclinic or through her website www.childrensallergyclinic.com.auSome other resources we mention include:ASCIA Allergy Action PlansEp. 118 – Introducing Allergens with Dr Chaitanya BodapatiEp. 119 – What to Do if Your Child Has an Allergic Reaction with Dr Chaitanya BodapatiToday's episode is brought to you by Haakaa. Haakaa is a family-owned New Zealand brand committed to making motherhood simpler, easier, and greener. From their iconic breast pumps to their fresh food feeders and silicone freezer trays, Haakaa's range of safe, sustainable and non-toxic baby products are favourites in both of our homes. Whether you're breastfeeding, introducing solids, or prepping meals for your toddler, Haakaa offers practical solutions that support you every step of the way.You can use the code BOOBTOFOOD for 10% off your order at www.haakaa.co.nzFollow us on instagram @boobtofood to stay up to date with all the podcast news, recipes and other content that we bring to help make meal times and family life easier.Visit www.boobtofood.com for blogs and resources, to book an appointment with one of our amazing practitioners and more.Presented by Luka McCabe and Kate HolmTo get in touch please email podcast@boobtofood.com

The Science Pawdcast
Episode 9 Season 7: Shingles, Dog Context, and The Immune System with Dr. Mohseni

The Science Pawdcast

Play Episode Listen Later Apr 5, 2025 67:08 Transcription Available


Send us a textOn this week's show we dive into the hidden connections between shingles vaccines and decreased dementia risk, while exploring how humans often misinterpret their pets' emotions based on environmental context rather than actual animal behavior.  Our guest, Dr. Yasmin Mohseni blows us away with the inner workings of the immune system.Some highlights:• Shingles vaccine study reveals a 20% reduction in dementia risk, particularly among women• The protective effect may be linked to how viral infections modify the immune system• Humans heavily rely on situational context rather than dogs' body language when assessing canine emotions• A study of 400 college students showed they couldn't distinguish dog emotions without environmental cues• Dr. Yasmin Mohseni explains why the immune system isn't a simple on/off switch that can be easily "boosted"• Immunotherapy approaches like CAR T-cell therapy are revolutionizing cancer treatment• Cancer cells create "fortress-like" defenses that engineered immune cells must overcome• Understanding your pet's actual body language rather than situational context can improve communicationDr. Yasmin's links:Instagram: https://www.instagram.com/doctor.yas_/Our links! Our Website!  www.bunsenbernerbmd.comSign up for our Weekly Newsletter!Bunsen and Beaker on Twitter:Bunsen and Beaker on TikTokSupport the showFor Science, Empathy, and Cuteness!Being Kind is a Superpower.https://twitter.com/bunsenbernerbmd

People of Pathology Podcast
Episode 201: Ashley Kalinauskas - How Torigen is Innovating Veterinary Oncology With Immunotherapy

People of Pathology Podcast

Play Episode Listen Later Mar 31, 2025 45:27


My guest today is Ashley Kalinauskas, CEO of Torigen Pharmaceuticals. What we discuss with Ashley: How her graduate research at Notre Dame led to the founding of Torigen Pharmaceuticals. Their approach provides an alternative to chemotherapy by using immunotherapy. The company aims to make cancer treatment more accessible and affordable for pet owners. Promising results have been seen in aggressive cancers like hemangiosarcoma. How Torigen is utilizing digital pathology with the Concentriq platform to improve cancer diagnostics. Torigen is conducting research into additional applications, including equine and exotic animal cancers. Studying spontaneous cancer in pets provides valuable insights for human oncology research. Veterinary immunotherapy advancements have the potential to influence human cancer treatments. Immunotherapy is playing an increasingly important role in both veterinary and human medicine.   Links for this episode: Pathologists' Assistant Shadowing Network Health Podcast Network  LabVine Learning Dress A Med scrubs Digital Pathology Club   Torigen Pharmaceuticals Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study New Hope For Pets In The Fight Against Cancer: Fast, Accurate Diagnoses From Torigen Pharmaceuticals And Proscia   People of Pathology Podcast: Twitter Instagram

Who's Tom & Dick
Farmer Giles

Who's Tom & Dick

Play Episode Listen Later Mar 28, 2025 33:20


Send us a textSeason 2, Episode 36Its a chance for the boy's to get together again today and have a chat.Although Martin gave us an update on his Cancer this week we delve into his current treatment "Immunotherapy" and its possible side effects.Immunotherapy uses our immune system to fight cancer. It works by helping the immune system recognise and attack cancer cells.You might have immunotherapy on its own or with other cancer treatments. Immunotherapy is a standard treatment for some types of cancer. And it is in clinical trials  for other types of cancer.There are different types of immunotherapy. We have information about the following types of immunotherapies:monoclonal antibodies (mAbs)checkpoint inhibitorsvaccinescytokinesCAR T-cell therapySome types of immunotherapies are also called targeted treatments or biological therapies. The boy's also talk about the touchy subject of Piles (Hemorrhoids) rhyming cockney slang "Farmer Giles" Piles, discussing diagnosis, causes and treatments.Hemorrhoids (HEM-uh-roids), also called piles, are swollen veins in the anus and lower rectum. Hemorrhoids are similar to varicose veins. Hemorrhoids can develop inside the rectum, called internal hemorrhoids. They also can develop under the skin around the anus, called external hemorrhoidsThere is also a chance for Martins Joke of the weekAnd don't forget if you live in the UK don't forget to put your clocks forward on Saturday night.#HeartTransplant#EbsteinsAnomaly#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#DNACheck out our new website at www.whostomanddick.comCheck out our website at www.whostomanddick.com

OncLive® On Air
S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

OncLive® On Air

Play Episode Listen Later Mar 27, 2025 15:16


In today's episode, OncLive teamed up with CURE to present a discussion with David A. Braun, MD, PhD, about his research on determinants of response to immune checkpoint inhibition (ICI) in patients with renal cell carcinoma (RCC). Dr Braun is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut. In this exclusive interview, Dr Braun discussed the rationale for investigating molecular factors that contribute to exceptional ICI responses among patients with RCC, as well as the key findings from this study. He also shared how these findings may affect cancer care and influence shared decision-making strategies for patients receiving immunotherapy.

FAACT's Roundtable
Ep. 227: The Caregiver Perspective on Oral Immunotherapy (OIT)

FAACT's Roundtable

Play Episode Listen Later Mar 26, 2025 21:53 Transcription Available


We're exploring how one family chose oral immunotherapy (OIT) for their child and what life has been like since they made that decision. Food allergy parent, advocate, and blogger, Hillary Tolle Carter is sharing her family's OIT journey with us today!Resources to keep you in the know:Hillary Tolle Carter - WebsiteHillary Tolle Carter - WebMD BlogsFollow Hillary on InstagramYou can find FAACT's Roundtable Podcast on Apple Podcast, Pandora, Spotify, Podbay, iHeart Radio or wherever you listen to your podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsor: ARS PharmaThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Finding Genius Podcast
The Power Of T-Cell Immunology: Early Diagnosis, Immunotherapy, & The Future Of Global Health

Finding Genius Podcast

Play Episode Listen Later Feb 28, 2025 43:18


In today's episode, we dive into the wonders of T-cell immunology technology and how it impacts early treatment interventions with long-time drug developer Dr. Nigel McCracken. As the Chief Operating Officer of Virax Biolabs, Dr. McCracken has more than 25 years of research and development experience in this diverse field – including oncology and infectious disease… Virax Biolabs is committed to revolutionizing global health by accelerating the development of more effective vaccines. How do they achieve this? By harnessing cutting-edge diagnostics to power a groundbreaking T-cell immunology platform, enabling early detection of post-viral syndromes and conditions linked to chronic inflammation and T-cell exhaustion. Before joining Virax, Dr. McCracken served as Chief Scientific Officer at BerGenBio ASA, where he led the development of companion diagnostics and assay strategies. Prior to that, he was COO at NuCana PLC, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment outcomes. In this role, he oversaw business operations, research and development, and the execution of corporate strategy. Tune in now to learn about: The importance of early diagnosis when it comes to immune system dysfunction. How the complementary system interacts with the immune system.  The typical role that T-cells play in infections.  Why chronic health problems are on the rise, and what this could mean for the future of healthcare. You can follow along with Dr. McCracken's work at Virax Biolabs here! Episode also available on Apple Podcasts: https://apple.co/30PvU9C Upgrade Your Wallet Game with Ekster!  Get the sleek, smart wallet you deserve—and save while you're at it! Use coupon code FINDINGGENIUS at checkout or shop now with this exclusive link: ekster.com?sca_ref=4822922.DtoeXHFUmQ5  Smarter, slimmer, better. Don't miss out!